BACKGROUND: @entity1 undergoing breast surgery are at particular risk for post-operative @entity1209 (PONV), with an incidence of @entity391 as high as 50% when no prophylactic antiemetic is used. OBJECTIVE: This study compared the efficacy of the selective @entity750 (3) receptor antagonist @entity10442 with that of the traditional antiemetics @entity6918 and @entity1769 in the treatment of established PONV after breast surgery. METHODS: In this prospective, randomized, double-blind trial, @entity1 who had undergone breast surgery and were experiencing PONV during the first 3 hours after anesthesia received either @entity10442 40 microg/kg IV, @entity6918 20 microg/kg IV, or @entity1769 0.2 mg/kg IV. @entity1 were observed for 24 hours after administration of study drug. @entity2749 were recorded by nursing staff who were blinded to treatment assignment. RESULTS: Seventy-five @entity1 were enrolled in the study, 25 in each treatment group. Their age ranged from 41 to 65 years. There were no significant between-group differences in @entity1 ' demographic or surgical characteristics at study entry. The number of @entity1 who were @entity391 free (no @entity390 , @entity391 ) was significantly higher in @entity1 who received @entity10442 (88% [2225]) than in those who received @entity6918 (64% [1625]; P = 0.047) or @entity1769 (56% [1425]; P = 0.013). In @entity1 who experienced @entity390 (3, 8, and 9 @entity1 in the @entity10442 , @entity6918 , and @entity1769 groups, respectively), the severity of @entity390 was significantly lower with @entity10442 compared with @entity6918 (P = 0.028) and @entity1769 (P = 0.025). No clinically serious adverse events were observed in any group. CONCLUSION: @entity10442 was significantly more effective than the traditional antiemetics @entity6918 and @entity1769 for the treatment of PONV in this population of @entity1 undergoing breast surgery.

A comparison of @entity10442 , @entity6918 , and @entity1769 in the treatment of established XXXX after breast surgery: a double-blind, randomized, controlled trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Women'] @entity2749 :: ('MESH:C580065', 'Disease') :: ['Emetic episodes'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['retching, or vomiting', 'emesis'] @entity6918 :: ('MESH:D004329', 'Chemical') :: ['droperidol'] @entity10442 :: ('MESH:D017829', 'Chemical') :: ['granisetron', 'Granisetron'] @entity1769 :: ('MESH:D008787', 'Chemical') :: ['metoclopramide'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['5-hydroxytryptamine'] @entity1209 :: ('MESH:D020250', 'Disease') :: ['nausea and vomiting']
@entity1209 :: (MESH:D020250,Disease) :: ['nausea and vomiting']
